dlbcl
Showing 1 - 25 of 48
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)
Recruiting
- B-cell Lymphoma
- +5 more
- Cyclophosphamide
- +3 more
-
Louisville, KentuckyNorton Cancer Institute
Jan 24, 2023
CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)
Recruiting
- CLL
- +9 more
- TG-1801
- Ublituximab
-
Fayetteville, Arkansas
- +4 more
Jan 20, 2023
Phase 1, NSCLC, SCLC Trial in United States (Oral MRT-2359)
Recruiting
- NSCLC
- +6 more
- Oral MRT-2359
-
Scottsdale, Arizona
- +7 more
Dec 20, 2022
Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)
Recruiting
- Diffuse Large B Cell Lymphoma
- +2 more
- Rituximab
- +5 more
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Dec 12, 2022
DLBCL, DLBCL Trial in Worldwide (Zilovertamab vedotin, Rituximab, Gemcitabine)
Recruiting
- DLBCL
- Diffuse Large B-Cell Lymphoma
- Zilovertamab vedotin
- +4 more
-
Whittier, California
- +21 more
Nov 30, 2022
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL Trial in United States (KT-413)
Recruiting
- Non Hodgkin Lymphoma
- +3 more
-
Washington, District of Columbia
- +5 more
Nov 29, 2022
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) Trial in Augusta, Nashville, Houston
Recruiting
- Mantle Cell Lymphoma
- +9 more
- L-Bcl-2 antisense oligonucleotide
-
Augusta, Georgia
- +2 more
Nov 18, 2022
Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in United Kingdom, United States (AUTO3)
Active, not recruiting
- Diffuse Large B Cell Lymphoma
- +3 more
- AUTO3
-
Duarte, California
- +10 more
Oct 19, 2022
Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)
Recruiting
- Large B-cell Lymphoma
- DLBCL
- 89Zr-DFO-REGN3767
- PET/CT
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Oct 3, 2022
DLBCL Trial in Hangzhou (Tafasitamab and Lenalidomide)
Recruiting
- DLBCL
- Tafasitamab and Lenalidomide
-
Hangzhou, Zhejiang, ChinaThe First Afflicated Hospital, College of Medicine, Zhejiang Uni
Sep 21, 2022
AML Including AML de Novo and AML Secondary to MDS, DLBCL Trial (Birabresib Dose 20 mg)
Terminated
- AML Including AML de Novo and AML Secondary to MDS
- DLBCL
- Birabresib Dose 20 mg
- (no location specified)
Aug 23, 2022
DLBCL Trial in Qingdao (Selinexor combined with Prednisone, Etoposide, and Lenalidomide)
Not yet recruiting
- DLBCL
- Selinexor combined with Prednisone, Etoposide, and Lenalidomide
-
Qingdao, Shandong, Chinathe affiliated hospital of Qingdao University
Aug 18, 2022
DLBCL Trial in China (Orelabrutinib and Gemox)
Not yet recruiting
- DLBCL
- Orelabrutinib and Gemox
-
Chongqing, Chongqing, China
- +7 more
Jul 5, 2022
DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)
Recruiting
- DLBCL
- +3 more
-
Minneapolis, MinnesotaUniversity of Minnesota, Masonic Cancer Center
Jul 1, 2022
DLBCL Trial in United States (MB-CART2019.1)
Recruiting
- DLBCL
- MB-CART2019.1
-
Gilbert, Arizona
- +14 more
Jun 17, 2022
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Recruiting
- DLBCL
- +8 more
- Cardiac MRI
-
Bonn, NRW, GermanyUniversity Hospital Bonn
Jun 11, 2022
Primary Extranodal Lymphoma, DLBCL Trial (Camrelizumab)
Not yet recruiting
- Primary Extranodal Lymphoma
- DLBCL
- (no location specified)
Apr 6, 2022